期刊文献+

胃癌术后辅助化疗药物研究现状 被引量:2

原文传递
导出
摘要 胃癌发病率最高的地区集中在东南亚和中国。手术是目前唯一可能治愈胃癌的手段,但近2/3的患者确诊时已是进展期,术后复发和转移率较高,5年生存率不足50%。术后辅助化疗是改善患者远期生存的主要方法,大量研究显示Ⅲ期胃癌术后辅助化疗可以明显提高患者的生存率,
机构地区 解放军总医院
出处 《医学临床研究》 CAS 2013年第4期788-790,共3页 Journal of Clinical Research
  • 相关文献

参考文献18

  • 1Herszenyi L, Tulassay Z. Epidemiology of gastrointestinaland liver tumors[J]. Eur Rev Med Pharmacol Sci ,2010,14(4):249-258.
  • 2Brenner H. Epidemiology of stomach cancer[J]. Methods MolBiol ,2009,472(4): 467-477.
  • 3Zhao SL, Fang JY. The role of postoperative adjuvant chem-otherapy following curative resection for gastric cancer: ameta_analysis[J]. Cancer Invest .2008; 26(3):317-325.
  • 4Macdonald JS. Role of post-operative chemoradiation in resec-ted gastric cancer[J]. J Surg Oncol ,2005,90(3) : 166-167.
  • 5GASTRIC (Global Advanced/Adjuvant Stomach Tumor Re-search International Collaboration) Group, Benefit of adju-vant chemotherapy for resectable gastric cancer: a meta-anal-ysis[J]. JAMA ,2010,303(17) = 1729-1733.
  • 6Petrovic Z, Tarabar D, Doder R, et al . Oxaliplatin (L-OHP)and capecitabine (X) as second-line chemotherapy in patientswith advanced gastric cancer (abstract 1199)[J]. Proc AmSoc Clin Oncol ,2003,22(1) : 29.
  • 7Park YH, Kim B-S, Ryoo B-Y . Oxaliplatin and capecitabinecombination chemotherapy for patients with advanced gastriccarcinoma: a pilot study results (abstract 57)[J]. Presentedat the second annual American Society of Clinical OncologyGastrointestinal Cancers Symposium, Miami, Florida ,2005:27-29.
  • 8Park YH, Kim BS, Ryoo BY,et al . h phase H study ofcapecitabine plus 3-weekly oxaliplatin as first-line therapy forpatients with advanced gastric cancer [ J]. Br J Cancer,. 2006,94C7):959-963.
  • 9Sumpter K, Harper-Wynne C, Cunningham et al . Reportof two protocol planned interim analyses in a randomisedmulticentre phase 瓜 study comparing capecitabine with flu-orouracil and oxaliplatin with cisplatin in patients with ad-vanced oesophagogastric cancer receiving ECF [ J ]. Br JCancer,2005,92(11) : 1976-1983.
  • 10Bang YJ,Kim YW, Yang HK, et al . Adjuvant capecitabineand oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC) : a phase 3 open-label, randomised controlledtrial[J]. Lancet ,2012,379(9813):315-321.

同被引文献20

  • 1Gravalos C Jimeno. A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target [ J]. Ann Oncol, 2008,19 (9) :1523-1529.
  • 2Chauhan SC, Vannatta K, Ebeling MC, et al. Expression and functions of transmembrane mucin MUC13 in ovarian cancer [ J 1. Cancer Res ,2009,69 ( 3 ) :765-774.
  • 3Bilous M, Osamura RY, Ruschoff J, et al. HER-2 amplification is highly homogenous in gastric cancer[ j]. Hum Pathol,2010,41 (2) :304-305.
  • 4Jorgensen Jr. Targeted HER2 Treatment in Advanced Gastric Cancer[J]. Oneology, 2010, 78(1): 26-33.
  • 5Park DI, Yun JW, Park JH, et al. HER-2/neu amplification is an independent prognostic factor in gastrieeancer [ J ]. Dig Dis Sci, 2006,51 (8) :1371-1379.
  • 6Ruschoff J, Nagelmeier I, Baretton G, et al. Her2 testing in gas- tric cancer. What is different in comparison to breast cancer[ J]. Der Pathologe, 2010,31 (3) :208-217.
  • 7Tanner M, Hollmen M, Junttila TI?, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase Ilalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab [ J ]. Ann Oncol, 2005,16 ( 2 ) : 273- 278.
  • 8Grabseh H, Sivakumar S, Gray S,et al. HER2 expression in gas- tric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series [ J ]. Cell Oncol, 2010,32(1-2) :57-65.
  • 9Kim, Hwang Phil1, Kim, et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification syner- gistically with cisplatin[ J]. Int J 0ncol,2008,32( 1 ) :89-95.
  • 10宋岩,黄镜,王金万.HER2/neu基因扩增和蛋白表达与晚期胃癌患者预后的关系[J].癌症,2010,29(1):76-81. 被引量:25

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部